Paturel Alexia, Hall Janet, Chemin Isabelle
Université de Lyon, Université Claude Bernard Lyon 1, INSERM, CNRS, Centre Léon Bérard, Centre De Recherche En Cancérologie De Lyon, 69008 Lyon, France.
Cancers (Basel). 2022 Aug 5;14(15):3806. doi: 10.3390/cancers14153806.
Primary liver cancer is the sixth most common cancer in men and seventh in women, with hepatocellular carcinoma (HCC) being the most common form (75-85% of primary liver cancer cases) and the most frequent etiology being viral infections (HBV and HCV). In 2020, mortality represented 92% of the incidence-830,180 deaths for 905,677 new cases. Few treatment options exist for advanced or terminal-stage HCC, which will receive systemic therapy or palliative care. Although radiotherapy is used in the treatment of many cancers, it is currently not the treatment of choice for HCC, except in the palliative setting. However, as radiosensitizing drugs, such as inhibitors of DNA repair enzymes, could potentiate the effects of RT in HCC by exploiting the modulation of DNA repair processes found in this tumour type, RT and such drugs could provide a treatment option for HCC. In this review, we provide an overview of PARP1 involvement in DNA damage repair pathway and discuss its potential implication in HCC. In addition, the use of PARP inhibitors and PARP decoys is described for the treatment of HCC and, in particular, in HBV-related HCC.
原发性肝癌是男性中第六大常见癌症，女性中第七大常见癌症，其中肝细胞癌（HCC）是最常见的形式（占原发性肝癌病例的75 - 85%），最常见的病因是病毒感染（HBV和HCV）。2020年，死亡率占发病率的92%——905,677例新发病例中有830,180例死亡。对于晚期或终末期HCC，治疗选择很少，这些患者将接受全身治疗或姑息治疗。尽管放射疗法用于治疗多种癌症，但目前它并非HCC的首选治疗方法，除非在姑息治疗的情况下。然而，作为放射增敏药物，如DNA修复酶抑制剂，可通过利用这种肿瘤类型中发现的DNA修复过程的调节来增强放疗对HCC的疗效，放疗和此类药物可为HCC提供一种治疗选择。在本综述中，我们概述了PARP1在DNA损伤修复途径中的作用，并讨论其在HCC中的潜在意义。此外，还描述了PARP抑制剂和PARP诱饵在HCC治疗中的应用，特别是在HBV相关HCC中的应用。
